ADIL
Adial Pharmaceuticals, Inc.Company with tickers: ADIL
CIK
1513525
CUSIP
00688A304
Shares Outstanding
2,143,621
13F Activity (30d)
9 filings
9 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,001,481 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Research & Development | $432,530 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $-2,001,481 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $-2,022,392 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $-1.48 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $-1.48 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |